# PRISMA 2020 Checklist

**Manuscript title:** Floor and Ceiling Effects in Thrombectomy: A Bayesian Hierarchical Ordinal Meta-analysis of 30 Randomized Trials

**Completed by:** Bradley Kolb, MD | **Date:** 2026-02-19

---

## TITLE

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 1 | Identify the report as a systematic review. | Title page (title includes "Meta-analysis of 30 Randomized Trials") |

---

## ABSTRACT

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 2 | See the PRISMA 2020 for Abstracts checklist. | Abstract section — Background, Purpose, Methods, Results, Conclusions all present |

---

## INTRODUCTION

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 3 | Describe the rationale for the review in the context of existing knowledge. | Introduction, paragraph 1–3 |
| 4 | Provide an explicit statement of the objective(s) or question(s) the review addresses. | Introduction, final paragraph ("We performed a Bayesian hierarchical ordinal meta-analysis…to test the floor/ceiling hypothesis") |

---

## METHODS

### Eligibility criteria

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 5 | Specify the inclusion and exclusion criteria for the review. | Supplementary Material — Eligibility Criteria section |

### Information sources

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 6 | Specify all databases, registers, websites, organisations, reference lists, and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted. | Methods, Data Sources ("We searched PubMed through October 2025"); Supplementary Material — Search Strategy |

### Search strategy

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 7 | Present the full search strategies for all databases, registers, and websites, including any filters applied, so that the searches could be repeated. | Supplementary Material — Search Strategy (full PubMed query provided) |

### Selection process

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 8 | Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved for eligibility, and any automation tools used in this process. | Supplementary Material — Study Selection section |

### Data collection process

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 9 | Specify the methods used to collect data from reports, including how many reviewers collected data from each report, any processes for obtaining or confirming data from study investigators, and if applicable, any automation tools used in the process. | Supplementary Material — Data Handling section |

### Data items

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 10a | List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, subgroups), and if not, the rationale for restricting data collected. | Methods, Statistical Model ("90-day modified Rankin Scale [mRS] distributions…from 30 trials") |
| 10b | List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). | Supplementary Material — Data Handling (trial-level characteristics in Table S1) |

### Study risk of bias assessment

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 11 | Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study, and any automation tools used in this process. | Supplementary Material — Risk of Bias Assessment section |

### Effect measures

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 12 | Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results. | Methods, Statistical Model (log odds ratio, proportional-odds ordinal model) |

### Synthesis methods

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 13a | Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned group for each synthesis). | Methods (all 30 eligible trials included in primary analysis) |
| 13b | Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing data, data conversions or imputation. | Methods, Statistical Model ("expanded published mRS distributions into category counts…using frequency weights") |
| 13c | Describe any methods used to tabulate or visually display results of individual studies and syntheses. | Results, Figures 1 and 2; Supplementary Figures S1 and S2 |
| 13d | Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. | Methods, Statistical Model and Implementation and Reproducibility (Bayesian hierarchical ordinal regression; brms/Stan) |
| 13e | Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression). | Methods (correlated intercept–slope model directly estimates relationship between heterogeneity in prognosis and treatment effect) |
| 13f | Describe any sensitivity analyses conducted to assess robustness of the synthesized results. | Methods, Implementation and Reproducibility ("three additional prespecified models") |

### Reporting bias assessment

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 14 | Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases). | Supplementary Material — Risk of Bias section (all 30 published trials with complete mRS data included; no imputation required) |

### Certainty assessment

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 15 | Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. | Supplementary Material — Risk of Bias (Cochrane RoB 2 tool applied; Table S2) |

---

## RESULTS

### Study selection

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 16a | Describe the results of the search and selection process, including reasons for exclusions at each stage of the process, and preferably incorporating a flow diagram. | Results, first paragraph; Supplementary Figure (PRISMA flow diagram) |
| 16b | Cite studies that might appear to meet the inclusion criteria but which were excluded, and explain why they were excluded. | Supplementary Material — Study Selection (excluded trials listed with reasons) |

### Study characteristics

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 17 | Cite each included study and present its characteristics. | Supplementary Table S1 (30 trials with key characteristics) |

### Risk of bias in studies

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 18 | Present assessments of risk of bias for each included study. | Supplementary Table S2 (Cochrane RoB 2 for all 30 trials) |

### Results of individual studies

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 19 | For all outcomes, present, for each study: (a) summary statistics for each group (if appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally in a structured table or plot. | Figure 1 (forest plot of trial-specific treatment effects); Supplementary Table S1 (mRS distributions) |

### Results of syntheses

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 20a | For each synthesis, briefly summarize the characteristics and risk of bias among contributing studies. | Results, all five subsections; Discussion |
| 20b | Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision and measures of statistical heterogeneity. | Results (common log OR 0·46; τ = 0·34; σ = 0·74; ρ = −0·51, all with 95% CrI) |
| 20c | Present results of all investigations of possible causes of heterogeneity among study results. | Results, "Trial-level relationship…" subsection; Figure 2 |
| 20d | Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. | Results, "Robustness and clinical translation" subsection; Supplementary Figure S1 |

### Reporting biases

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 21 | Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed. | Supplementary Material — Risk of Bias section |

### Certainty of evidence

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 22 | Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. | Supplementary Material — Risk of Bias (Table S2) |

---

## DISCUSSION

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 23a | Provide a general interpretation of the results in the context of other evidence. | Discussion, all three paragraphs |
| 23b | Discuss any limitations of the evidence included in the review. | Limitations section (five limitations addressed) |
| 23c | Discuss any limitations of the review processes used. | Limitations section (aggregate-data limitation noted) |
| 23d | Discuss implications of the results for practice, policy, and future research. | Discussion, "Clinical implications" paragraph; Conclusion |

---

## OTHER INFORMATION

### Registration and protocol

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 24a | Provide registration information for the review, including register name and registration number, or state that the review was not registered. | Methods, Implementation and Reproducibility (pre-registered at OSF: https://osf.io/smcen/) |
| 24b | Indicate where the review protocol can be accessed, or state that a protocol was not prepared. | Methods (OSF pre-registration: https://osf.io/smcen/) |
| 24c | Describe and explain any amendments to information provided at registration or in the protocol. | No amendments from pre-registered protocol |

### Support

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 25 | Describe sources of financial or other support for the review, and the role of the funders or sponsors in the review. | Funding statement: "None" |

### Competing interests

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 26 | Declare any competing interests of review authors. | Declaration of Interests (SM reports consulting fees from Medtronic, Inc.; all other authors declare no competing interests) |

### Availability of data, code, and other materials

| Item | Checklist Item | Reported on Page / Section |
|------|---------------|---------------------------|
| 27 | Report which of the following are publicly available and where they can be accessed: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. | Data Sharing statement (data and code available at https://github.com/brad-kolb/claude-code-my-workflow and https://osf.io/smcen/) |

---

*Reference: Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.*
